Ophthalmology Solution Articles & Analysis

1 articles found

Aramis Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease

Aramis Biosciences announced that the first patient has been dosed in its phase 2 proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease. “This is an important milestone for Aramis Biosciences and a hopeful moment for dry eye patients given the suboptimal efficacy and tolerability limitations commonly ...

Feb. 28, 2022

ByVEO Ophthalmics, LLC

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you